List View

By /

Clear

Displaying 1,976 - 2,000 of 2,573

Strategies to Target Minimal Residual Disease

Strategies to Target Minimal Residual Disease

Methylation, Proteomics and Other Efforts for Early Lung Cancer Detection

Methylation, Proteomics and Other Efforts for Early Lung Cancer Detection

Minimal Residual Disease (MRD) as Detected by Liquid Biopsy: Where are We Going?

Minimal Residual Disease (MRD) as Detected by Liquid Biopsy: Where are We Going?

Neoadjuvant Immunotherapy Position

Neoadjuvant Immunotherapy Position

Adjuvant Immunotherapy Position

Adjuvant Immunotherapy Position

MRD to Decide Perioperative Management in the Era of Immuno-Oncology

MRD to Decide Perioperative Management in the Era of Immuno-Oncology

Biomarkers for Perioperative Immunotherapy?

Biomarkers for Perioperative Immunotherapy?

Best Surgical Approaches for Stage III NSCLC

Best Surgical Approaches for Stage III NSCLC

Stage III Non-Surgical Candidate NSCLC – Controversies in this Arena (Tumors with Actionable Genes and No PD-L1 Expression)

Stage III Non-Surgical Candidate NSCLC – Controversies in this Arena (Tumors with Actionable Genes and No PD-L1 Expression)

Stage III Non-Surgical NSCLC: Optimal Radiation Therapy Approach

Stage III Non-Surgical NSCLC: Optimal Radiation Therapy Approach

What’s After PACIFIC? Can We Raise the Bar?

What’s After PACIFIC? Can We Raise the Bar?

How to Improve Targeted Therapy in NSCLC? Where are the Major Gaps?

How to Improve Targeted Therapy in NSCLC? Where are the Major Gaps?

Best Approaches for First Line EGFR Mutant NSCLC

Best Approaches for First Line EGFR Mutant NSCLC

How to Rescue Patients from Osimertinib Resistance

How to Rescue Patients from Osimertinib Resistance

Exon 20 and Uncommon EGFR Sensitive Mutations

Exon 20 and Uncommon EGFR Sensitive Mutations

Health Care Disparities in Lung Cancer Genomic Profiling

Health Care Disparities in Lung Cancer Genomic Profiling

Lack of Equity in Clinical Outcomes in African American and Hispanics with NSCLC

Lack of Equity in Clinical Outcomes in African American and Hispanics with NSCLC

ALK in Front Line Therapy: Second or Third Generation TKI Inhibitors. What Can Help Us to Choose the Best Therapeutic Agent?

ALK in Front Line Therapy: Second or Third Generation TKI Inhibitors. What Can Help Us to Choose the Best Therapeutic Agent?

Mechanisms of Resistance to ALK Inhibitors

Mechanisms of Resistance to ALK Inhibitors

ROS-1 & B-Raf Inhibitors: New Developments

ROS-1 & B-Raf Inhibitors: New Developments

RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up?

RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up?

KRAS mutant NSCLC: What is the Standard of Care Now?

KRAS mutant NSCLC: What is the Standard of Care Now?

KRAS: Deciphering the Mechanism of Resistance To First Generation KRAS Inhibitors

KRAS: Deciphering the Mechanism of Resistance To First Generation KRAS Inhibitors

Pan-KRAS Inhibitors: Where are We Going?

Pan-KRAS Inhibitors: Where are We Going?

Role of SHP2 Inhibitors Alone or in Combination

Role of SHP2 Inhibitors Alone or in Combination